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Abstract
Background Endoscopic mucosal resection (EMR) has been
proven to be safe and effective for the treatment of colorectal
adenomas. However, data are limited on the safety of this
technique for large polyps and in elderly patients. Aims of
our study were to examine the bleeding and perforation rates
in patients with large non-pedunculated adenomas (≥20mm)
and to evaluate the influence of size (≥40mm) and age (≥75
years) on the complication rates.
Methods In this multicenter retrospective study, patients who
underwent EMR of non-pedunculated adenomas ≥20mm be-
tween January 2012 and March 2016 were included. The de-
mographics of the patients, the use of antithrombotic drugs,
size of the polyps, type of resection, pathology report, occur-
rence of post-polypectomy bleeding, and perforation- and re-
currence rate were collected.
Results In 343 patients, 412 adenomas were removed. Eighty
patients (23.3%) were ≥75 years of age, 138 polyps (33.5%)
were ≥40mm. Bleeding complications were observed in 28
cases (6.8%) and were found significantly more frequent in
adenomas ≥40mm, independent of the use of antithrombotic
therapy. Five perforations (1.2%) were described, not related
to the size of the polyp. There was no significant difference in
complication rates between patients <75 years and patients
≥75 years. Bleeding complications rates were significantly
higher in patients receiving double antithrombotic therapy.
Conclusion EMR is safe in elderly patients. EMR of adeno-
mas of ≥40mm was associated with more bleeding complica-
tions. Future studies should address how the bleeding rates
can be reduced in these patients, especially in those who use
double antithrombotic treatment.
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Introduction
Colorectal cancer is the most commonly diagnosed cancer of
the gastro-intestinal tract. It is the leading cause of overall
cancer death in Western countries after lung cancer [1–7]. In
2012 in Europe, the incidence of colorectal cancer was 60 per
100.000 people, resulting in nearly half a million new cases
per year. The mortality rate of 29 per 100.000 accounted for
12.2% of all cancer deaths. The incidence of colorectal cancer
is increasing and it is expected to rise from 1.4 to 2.4 million
cases annually worldwide by 2035 [1, 2].
In many countries, population screening programs for the
detection of colorectal cancer have been implemented, usually
starting at the age of 50 or 55 and continuing until the age of
75 [5–8]. Screening tests including fecal occult blood test
(FOBT), sigmoidoscopy or colonoscopy are used to detect
early stage colorectal cancer and are proven effective in reduc-
ing mortality and morbidity rates [1, 5–7]. Such programs lead
to the detection of an increasing number of patients with large
adenomas [9]. Critics of the colorectal cancer screening pro-
grams point towards the lack of evidence for a decrease in
overall mortality, possibly due to the advanced age and
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extensive comorbidity in those found with colorectal cancer.
Detection and removal of large polyps in this frail patient
group has the potential to lead to morbidity and mortality that
could negate any positive effects of the screening [10]. To be
able to balance the health benefits with the risks, more infor-
mation as to the nature and extent of these risks in this sub-
group is required.
For the removal of large non-pedunculated polyps, en-
doscopic mucosal resection (EMR) is the usual treatment,
and is reported to be effective and safe [11–31]. However,
in polyps of ≥20mm, piecemeal resection is often required
which is associated with higher recurrence rates [11,
15–17, 20, 32, 33].
The prevalence and size of colorectal polyps increases with
age, so an increasing number of patients over the age of 75 are
likely to undergo EMR. Various studies have reported on the
complication rate of endoscopic resection in non-
pedunculated polyps ≥20mm [11, 14, 19, 27, 28, 34].
However, information about the complication rate of endo-
scopic resection of giant polyps (≥40mm) and in elderly pa-
tients (≥75 years) is limited [26, 27, 34, 35]. Therefore, aims
of our study were to examine the bleeding and perforation
rates of endoscopic polyp resection in patients with large
(≥20mm), non- pedunculated polyps and, in particular, to
evaluate the influence of size (≥40mm) and age (≥75 years)
on the complication rates.
Material and methods
This multicentre retrospective cohort study was performed
between January 2012 andMarch 2016. For this type of study,
formal consent was not required. Patients who had undergone
EMR for colorectal non-pedunculated polyps ≥20mm in
Leiden University Medical Centre (LUMC) and Isala in
Zwolle were included. Pedunculated polyps and malignant
appearing polyps which were biopsied and eventually not re-
moved by EMR were excluded in this study. All procedures
were performed by endoscopists who were accredited for the
Dutch National Bowel Screening Program. In addition, each
had performed at least 100 previous EMRs ≥2cm.
Procedure and equipment
According to the national guideline, anticoagulant therapy
(e.g. marcoumar, acenocoumarol) was stopped 3-5 days be-
fore the procedure and restarted on the same day after the
procedure [36, 37]. The decision to interrupt the use of anti-
platelet therapy (e.g. aspirin, clopidogrel, dypiridamol) was
evaluated per patient and per type of therapy. Patients using
double therapy were instructed to stop one of the antiplatelet
drugs before the procedure, in accordance with the guidelines
[36–38]. Aspirin could be continued. Double therapy was
resumed the day after the procedure. Participants received
bowel preparation consisting of picoprep or kleanprep. The
mode of sedation was assessed per patient. Most frequently,
endoscopic polyp resection was performed under conscious
sedation with midazolam and fentanyl. In longer procedures,
patients were sedated with propofol and remifentanyl under
supervision of an anaesthetic nurse specialist.
Procedures were performed under carbon dioxide insuffla-
tion using Olympus CF-HQ190L colonoscopes. The size of
the lesion was estimated by the endoscopist during colonos-
copy before resection by placing an open biopsy forceps
(8mm) next to the lesion. The standard inject-and-cut EMR
technique was applied by injecting a solution of Voluven
(Hydroxyethyl starch) plasma expander, indigo carmine and
in some cases a low concentration of epinephrine (1:100.000)
for mucosal lifting. Argon plasma coagulation (pulsed 2,
25W), adrenaline (1:10.000) or clips were used in the case
of bleeding. If necessary, e.g. in the case of visible vessels,
wounds were approximated by clips. APC was also used to
treat residual tissue in case of incomplete resection. All pa-
tients were observed for at least one hour. After an uncompli-
cated procedure they were discharged on the same day, or
occasionally after an overnight stay.
Histology
Adenomas containing >75% villous architecture were defined
as villous adenomas and those comprising 25-75% villous
architecture as tubulovillous. Focally present high-grade dys-
plasia (<10%) was considered as low-grade dysplasia.
Complications
Information on complications was obtained from patients’
electronic patient records including nursing and endoscopy
reports. Bleeding was defined as early (<48h after completion
of procedure) and delayed (>48h after completion of proce-
dure). Bleeding was registered as a complication when
resulting in hospital (re)admission, (re-)intervention and/or
therapy (e.g. repeat endoscopy, coiling, blood transfusion or
surgery). Clip placement, argon coagulation or adrenaline in-
jection to control bleeding during the initial colonoscopy was
not considered as a complication. Perforation was diagnosed
either periprocedurally by the endoscopist or by an abdominal
CT-scan. Minor damage to the muscle wall, which was man-
aged with clips was not defined as a complication, neither was
a (suspicion of) perforation that was directly treated during
colonoscopy that did not result in hospital admission. If a
complication occurred during the removal of multiple polyps
in one session, further investigation was performed to assess
which polyp caused the complication (bleeding/perforation).
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Follow-up
In all patients a control visit or telephone appointment was
planned about a month after colonoscopy to discuss histopath-
ologic outcomes and follow up. According to the Dutch
guidelines for colonoscopy surveillance, the follow-up endos-
copy interval depends on the histopathology report (architec-
ture, extent of dysplasia/carcinoma and margin of specimen),
the mode of removal (en bloc or piecemeal), the size and
number of the adenomas and the location in the colon [39].
If there is uncertainty histologically about the completeness of
polyp removal, a surveillance colonoscopy was scheduled 3-6
months later. During follow-up endoscopy, the scar was mac-
roscopically examined and biopsies were taken only in case of
a suspected lesion. Residual tissue was treated with cold snare,
APC or EMR. In two cases the endoscopy reports and patient
records were inconclusive as to whether residual tissue had
been detected and were therefore reported as missing and not
included in follow-up analysis. In all other cases this was
clearly documented.
Statistical analysis
Data collection and statistical analysis were performed by
means of descriptive statistics with IBM SPSS Statistics 23
and Microsoft Office Excel 2010. Fisher’s exact test was used
to compare categorical outcome variables. Differences were
considered significant if the two-sided P-value was <0.05.
Results
Study group
EMR of lesions ≥20mm was successfully performed in 343
patients (mean age of 67.4 (SD 8.3), male: n=201, (58.6%)).
One hundred and three patients (30.1%) used antithrombotic
drugs; 15.2% antiplatelet drugs, 11.1% anticoagulants and
3.8% double antiplatelet therapy. In sixty-nine patients, mul-
tiple lesions ≥20mm were removed, either in one or more
sessions. Table 1 shows an overview of patient and lesion
characteristics.
Lesion characteristics
A total of 412 lesions were reported, of which 138 (33.5%)
≥40mm. The mean size of the resected polyps was 32,3mm
(SD 13mm). Two hundred and five (50.2%) were sessile and
203 (49.8%) were flat (missing n=4). Most polyps (81.3%)
were resected piecemeal.
Table 1 Patient- and lesion characteristics
n %
Patient characteristics
Number of patients 343
Mean age (±SD) 67,4 ± 8,3
≥75yr (±SD) 80 (23,3%)









Antiplatelet therapy 52 (15,2%)
Anticoagulant therapy 38 (11,1%)
Double therapy 13 (3,8%)
Lesion characteristics
Number of lesions 412
Size
Mean (mm ±SD) 32,3 ± 13




Ileocecal valve 11 (2,7%)
Cecum 54 (13,1%)
Ascending colon 84 (20,4%)
Hepatic flexure 37 (9,0%)
Transverse colon 51 (12,4%)
Splenic flexure 26 (6,3%)





Sessile (0-Is) 205 (50,2%)
Flat (0-IIa, 0-IIb, 0-IIc) 203 (49,8%)
Histology
Tubulair adenoma 145 (37,2%)
Tubulovillous adenoma 168 (43,1%)
Villous adenoma 10 (2,6%)
Sessile serrated 50 (12,8%)
Other 17 (4,4%)
No dysplasia 52 (12,4%)
Low-grade dysplasia 301 (73,1%)
High-grade dysplasia 30 (7,3%)
Intramucosal carcinoma 11 (2,7%)
Invasive carcinoma 18 (4,4%)
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Histology
Of all 412 polyps, 145 lesions (37.2%) were tubular adeno-
mas, 158 (43.1%) were tubulovillous adenomas, 10 (2.6%)
were villous adenomas and 50 (12.8%) were sessile serrated
polyps. In 22 cases, growth patterns were not described in the
histology reports. Low grade dysplasia was the most common
pathology comprising 301 cases (73.1%). 11 cases (2.7%)
showed an intramucosal carcinoma and 18 cases (4.4%) an
invasive adenocarcinoma. R0 resection was achieved in
20.8% of all en bloc resections.
Complications
Table 2 provides an overview of the complications per lesion
in this study. Detailed results on complications are presented
in Tables 3, 4, 5 and 6.
Total bleeding complication rate was 6.8% (28 cases)
and occurred significantly more in polyps ≥40mm com-
pared to polyps 20-40mm (10.9% vs. 4.7%, p=0.04). No
significant difference was observed in antithrombotic drug
use between polyps 20-40mm and ≥40mm (p=0.252).
Twice as many bleeding complications occurred when
using antithrombotic therapy (10.8% vs. 5.1%, p=0.051),
especially double therapy (31%, p=0.002) (Tables 5 and
6). No significant difference was observed in patients <75
years vs. patients ≥75 years (6.2% vs. 9.3%, p=0.33).
There was one patient who had both an early and delayed
bleeding.
Early bleeding <48h: In 19/412 cases (4.6%) early bleed-
ing was reported. Thirteen of these nineteen cases underwent
repeat colonoscopy; four cases needed additional blood trans-
fusion. In the remaining six cases, no colonoscopy was per-
formed. Two of these six patients received a blood transfusion
and were sent for angiographic embolisation, the other four
were managed conservatively. The mean hospital stay was 2.1
days (range 0-5 days).
There was no significant elevated risk in early bleeding for
polyps ≥40mm compared to polyps 20-40mm (6.5% vs.
3.6%; p=0.216) and for patients ≥75 years compared to pa-
tients <75years (5.8% vs. 4.3%; p=0.565). The use of
antithrombotics resulted in more early bleeding. However,
the difference was not significant (7.5% vs. 3.4%; p=0.117)
(Table 5), and mainly due to double antithrombotic use
(p=0.004) (Table 6).
Delayed bleeding >48h. In 9 of 412 lesions (2.2%) patients
were admitted to the hospital for delayed bleeding and all
patients underwent repeat colonoscopy. Three cases required
blood transfusion. No CT intervention was needed. The mean
hospital stay was 1.9 days (range 0-4 days).
Delayed bleeding occurred more in polyps ≥40mm
compared to polyps 20-40mm (4.3% vs. 1.1%; p=0.066),
however this was not significant. No significant difference
was found in delayed bleeding complications in patients
≥75 years compared to patients <75 years. (3.5% vs.
1.8%; p=0.400). Almost twice as many delayed bleeding
complications occurred in patients using antithrombotic
drugs compared to patients not using antithrombotic drugs
(3.3% vs. 1.7%; p=0.293), but this difference was not
significant (Table 5).
Perforation Five (1.2%) perforations occurred. One case was
managed conservatively, and three cases were successfully
closed with clips during the initial endoscopy. Surgical inter-
vention was needed in one case.
Table 2 Complications and follow-up
n (%)
Number of lesions 412
Technique
En bloc 77 (18,7%)
R0 resection 15 (20,8%)
Piecemeal 335 (81,3%)
Complications
Total bleeding complications 28 (6,8%)
Early bleeding <48h 19 (4,6%)




Residual tissue 55 (18.8%)
Enbloc 4 (7.3%)
Piecemeal 51 (92.7%)
Table 3 Complications versus polyp size and patients’ age
20-40mm (n=274) ≥40mm (n=138) p value <75jr (n=326)* ≥75jr (n=86)* p value
Total bleeding complications (n=28) 13 (4.7%) 15 (10.9%) 0,036 20 (6.2%) 8 (9,3%) 0,331
Early bleeding (n=19) 10 (3,6%) 9 (6,5%) 0,216 14 (4,3%) 5 (5,8%) 0,565
Delayed bleeding (n=9) 3 (1.1%) 6 (4.3%) 0,066 6 (1.8%) 3 (3,5%) 0,400
Perforation (n=5) 3 (1,1%) 2 (1,4%) 1,000 5 (1,5%) 0 0,588
*evaluated per lesion
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No significant difference in perforation rate was observed
between resection of 20-40 mm and the resection of polyps
larger than 40mm (1.1% vs. 1.4%, p=1.000). No perforations
occurred in elderly patents above the age of 75 (1.5% vs. 0%,
p=0.588).
Other complications In total, three complications were
observed. One patient was admitted for observation after
possible aspiration at the end of a colonoscopy under
propofol sedation. She was discharged the next day with
oral antibiotics without further complications. Another pa-
tient was observed after having a post procedural epileptic
insult after discharge. Midazolam/fentanyl was used dur-
ing endoscopy. Lastly, one patient experienced a painless
pneumoscrotum directly after the procedure using
propofol without further complications..To the best of
our knowledge, no cardiovascular events occurred and
no deaths related to colonoscopy were observed.
Surgery
Surgical resection after polypectomy was performed in 16
cases (3.9%). In one patient, surgical intervention was per-
formed because of a perforation during endoscopy. In 15 of
these 16 cases, additional surgical resection was performed
because of malignant histology of the resected polyp. In five
of these fifteen cases, residual carcinoma was found in the
surgical specimen. In nine of the fifteen cases, no malignancy
was found. One case was lost to follow up as the patient
underwent surgery in another hospital.
Follow-up data
In 292 out of 412 (70.9%) cases, a follow-up colonoscopy was
performed with a mean follow-up time of 6.94 months (SD
5.94 months, 95% CI 6.26-7.63 months).
The remaining cases included patients either awaiting a
first follow-up procedure (n=61), patients without indication
for surveillance (e.g. comorbidity, advanced age, or colon re-
section (n=41)), patients lost to follow-up (n=9) or patients
refusing follow-up (n=9).
Assessment of polyp removal sites mostly occurred by
macroscopic examination of the scar. Residual tissue/
recurrence was found in 55/292 (18.8%) lesions, and was
treated with snare or APC. Most residual tissue was found
after piecemeal removal, in 51/55 cases (92.7%, p<0.05).
Discussion
The present study supports the premise that EMR of large
non-pedunculated polyps is safe in elderly (≥75 years) pa-
tients. EMR of giant adenomas (≥40mm) is associated with
more bleeding complications but did not lead to more
perforations.
Various studies have reported on complication rates after
EMR. However, information about the complication rate of
EMR of giant polyps and EMR in elderly patients is limited
[26, 27, 34, 35]. Our retrospective study evaluated the out-
comes and safety of EMR in a large cohort of patients who
underwent EMR of polyps ≥20mm. A quarter of the study
group were 75 years or older and one third had lesions of more
than 40mm.
The overall complication rates observed in our patients
were within the range reported in the literature; early bleeding
0-7.9% and delayed bleeding 0-2.3% [11, 14, 19, 27, 28, 34,
40]. We did not observe any deaths due to the interventions.
Some studies have reported increased complication rates
(bleeding and perforations) of endoscopic removal of larger
lesions ≥30mm [12, 23, 26, 35]. The perforation rate of our
study in patients with polyps ≥40mm was similar to the per-
foration rate in patients with polyps of 20-40mm. These find-
ings are in agreement with the study by Luigiano et al. [27] On
Table 4 Antithrombotic therapy
in relation to polyp size 20-40mm (n=274) ≥40mm (n=138) p value
Antithrombotic therapy* (n=120) 85 (31,0%) 35 (25,4%) 0,252
No antithrombotic therapy* (n=292) 189 (69,0%) 103 (74,6%)
*evaluated per lesion
Table 5 Bleeding complications





Total bleeding complications (n=28) 13 (10.8%) 15 (5,8%) 0,051
Early bleeding (n=19) 9 (7,5%) 10 (3,4%) 0,117
Delayed bleeding (n=9) 4 (3.3%) 5 (1.7%) 0,293
*evaluated per lesion
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the other hand, we found a significantly higher total bleeding
complication rate in polyps larger than 40mm compared to 20-
40mm polyps. This finding could not be explained by differ-
ences in antithrombotic drug use between both groups.
Sahwney et al. have also reported lesion size as an indepen-
dent predictive factor of post polypectomy bleeding [41].
In elderly patients (≥75 years) we did not find significantly
more bleeding complications. Also, no perforations were
observed in these patients. Gómez et al. evaluated the
outcomes and safety of colorectal EMR in patients older
than 80 years [34]. They reported a total bleeding rate of
2.3%, and a perforation rate of 3%. The authors conclud-
ed that EMR for the removal of polyps ≥20mm in elderly
patients is safe.
Overall bleeding complications were more frequently ob-
served when antithrombotic drugs were used (borderline sig-
nificant=0.051), in particular, in patients who used double
antiplatelet therapy (P<0.05). Guidelines on endoscopy in pa-
tients with antithrombotic therapy advise to stop one of anti-
platelet drugs when using double therapy 5-7 days before the
procedure [36–38]. The other drug can be continued, which is
mainly aspirin. Less is known regarding timing of reinitiation
of the antiplatelet drug [38]. The drug is restarted the day after
the procedure, according to the guidelines [37, 38]. Based on
our results we would recommend to consider postponement of
restarting the antiplatelet drug after the procedure as we ob-
served significantly more early bleeding complications in pa-
tients using double therapy. Numbers are however small and
future prospective studies should reveal after how many days
the risk of bleeding has reduced after large EMR.
Residual tissue or recurrence was observed in 18.8%,
which is within the range reported in literature (4.2-40%)
[11, 14, 19, 27, 28, 34]. However, our percentage might
be an underestimate because scars were not routinely
biopsied. Most residual tissue was found, as expected,
after piecemeal removal.
This study adds significantly to the existing literature due
to its large size, the high proportion of elderly people and the
large number of giant adenomas. A further positive aspect is
that we were fully informed about the occurrence of compli-
cations after polypectomy. The limitations of our study are its
retrospective design and lack of routine biopsies of the
polypectomy site at the follow-up colonoscopies.
In conclusion, the implementation of screening programs
worldwide has led to the detection of increasing numbers of
large non-pedunculated adenomas, often in elderly patients.
This number is likely to increase further due to population
ageing and higher life expectancy. Since surgical removal of
giant adenomas at an advanced age is associated with a sub-
stantial mortality (5%), endoscopical removal is increasingly
performed [42]. Our study showed that EMR is a safe proce-
dure for both elderly patients above age of 75 and for non-
pedunculated colorectal polyps larger than 40mm, although it
is associated with significant morbidity, largely due to bleed-
ing. Improved methods are needed to reduce post
polypectomy bleeding in patients that use antithrombotic
treatments and with giant (≥40mm) polyps.
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